Can-Fite BioPharma (CANF) Profit After Tax (2014 - 2023)

Can-Fite BioPharma (CANF) has 10 years of Profit After Tax data on file, last reported at -$1.7 million in Q4 2023.

• Quarterly Profit After Tax fell 244.17% year-over-year to -$1.7 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$8.9 million (down 16.36% YoY) and the FY2025 annual result came in at -$9.8 million, down 224.72% from the prior year.
• Profit After Tax climbed to -$1.7 million in Q4 2023, from -$1.8 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $7.0 million in Q2 2021 to a low of -$21.1 million in Q4 2021.
• A 5-year average of -$2.8 million and a median of -$2.6 million in 2020 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2019 — Profit After Tax plunged 1565.54% — and 2021, when it jumped 279.17%.
• Tracing CANF's Profit After Tax over 5 years: stood at -$4.8 million in 2019, then increased by 24.06% to -$3.6 million in 2020, then plunged by 481.12% to -$21.1 million in 2021, then soared by 97.73% to -$480000.0 in 2022, then sank by 244.17% to -$1.7 million in 2023.
• The last three Profit After Tax figures came in at -$1.7 million (Q4 2023), -$1.8 million (Q3 2023), and -$2.8 million (Q2 2023), per Business Quant data.